Intensive Chemotherapy (IC) is More Effective than Hypomethylating Agents (HMA) for the Treatment of Younger Patients with Myelodysplastic Syndrome (MDS) and Elevated Bone Marrow Blasts

Lignende værker

• Acute myeloid leukemia: current progress and future directions
  af: Kantarjian, Hagop, et al.
  Udgivet: (2021)
• Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
  af: Takahashi, Koichi, et al.
  Udgivet: (2016)
• Impact of Achievement of Complete Cytogenetic Response on Outcome in Patients with Myelodysplastic Syndromes Treated with Hypomethylating Agents
  af: Jabbour, Elias, et al.
  Udgivet: (2017)
• FAILURE OF HYPOMETHYLATING AGENT-BASED THERAPY IN MYELODYSPLASTIC SYNDROMES
  af: Kadia, Tapan M., et al.
  Udgivet: (2011)
• Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes
  af: Daver, Naval, et al.
  Udgivet: (2014)